Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Highlights:NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publicati...
Source: businessinsider.com
Colorectal Dysfunction News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Colorectal Dysfunction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Colorectal Dysfunction Today - Breaking & Trending Today
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...
Source: prnewswire.com
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Highlights: MELBOURNE, Australia, Jan. 27, 2022 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2021 (Q2 FY22). The Company's cash position on...
Source: asiaone.com
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Highlights: NZ’s regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications...
Source: fnarena.com
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
Source: prnewswire.com